---
layout: default
title: Famotidine
description: "Famotidine çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 69
evidence_level: L1
indication_count: 10
---

# Famotidine

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Famotidine è—¥å¸«è©•ä¼°ç­†è¨˜

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Famotidine å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Famotidine æ˜¯ H2 å—é«”æ‹®æŠ—åŠ‘ï¼ŒTxGNN é æ¸¬å…¶å¯ç”¨æ–¼åäºŒæŒ‡è…¸èƒƒé£Ÿé“é€†æµå’Œæ¶ˆåŒ–æ€§æ½°ç˜ï¼Œé€™äº›é æ¸¬èˆ‡åŸæ ¸å‡†é©æ‡‰ç—‡é«˜åº¦é‡ç–Šï¼Œå…·æœ‰å……åˆ†çš„è‡¨åºŠè­‰æ“šæ”¯æŒã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| è—¥ç‰©åç¨± | Famotidine (æ³•è«æ›¿ä¸) |
| DrugBank ID | DB00927 |
| å°ç£å•†å“å | è«¾å¾—èˆ’èƒƒç¦æ²»æ½°è†œè¡£éŒ  |
| åŸæ ¸å‡†é©æ‡‰ç—‡ | èƒƒæ½°ç˜ã€åäºŒæŒ‡è…¸æ½°ç˜ã€é€†æµæ€§é£Ÿé“ç‚ã€Zollinger-Ellison ç—‡å€™ç¾¤ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | peptic esophagitisã€gastrin secretion abnormalityã€duodenogastric refluxã€duodenal obstructionã€duodenal ulcer (disease)ã€active peptic ulcer diseaseã€peptic ulcer perforationã€gastrojejunal ulcerã€esophagitis (disease)ã€Zollinger-Ellison syndrome |
| æœ€é«˜é æ¸¬åˆ†æ•¸ | 0.9999 (duodenogastric reflux) |
| è­‰æ“šç­‰ç´š | L2 (å–®ä¸€ RCT/å¤šå€‹ Phase 2) |



## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. duodenogastric reflux</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.99%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p>Famotidine çš„é æ¸¬é©æ‡‰ç—‡èˆ‡å…¶å·²çŸ¥è—¥ç†æ©Ÿè½‰é«˜åº¦ä¸€è‡´ï¼š</p>

<ol>
<li><strong>èƒƒé…¸æŠ‘åˆ¶æ©Ÿè½‰</strong>ï¼šH2 å—é«”æ‹®æŠ—åŠ‘å¯æ¸›å°‘èƒƒé…¸åˆ†æ³Œï¼Œæ˜¯æ²»ç™‚æ¶ˆåŒ–æ€§æ½°ç˜çš„ç¶“å…¸æ©Ÿè½‰</li>
<li><strong>é»è†œä¿è­·</strong>ï¼šæ¸›å°‘èƒƒé…¸å¯é™ä½èƒƒé»è†œæå‚·ï¼Œä¿ƒé€²æ½°ç˜ç™’åˆ</li>
<li><strong>é©æ‡‰ç—‡é‡ç–Š</strong>ï¼šé æ¸¬çš„é©æ‡‰ç—‡å¯¦éš›ä¸Šæ˜¯åŸæ ¸å‡†é©æ‡‰ç—‡çš„å»¶ä¼¸æˆ–ç´°åˆ†</li>
<li><strong>è‡¨åºŠå¯¦å‹™ä¸€è‡´</strong>ï¼šé€™äº›é æ¸¬åæ˜ äº† famotidine çš„å¯¦éš›è‡¨åºŠä½¿ç”¨ç¯„åœ</li>
</ol>

<h3>è‡¨åºŠè©¦é©—</h3>

<p>### ClinicalTrials.gov æœå°‹çµæœ</p>

<table>
<thead>
<tr>
<th>è©¦é©—ç·¨è™Ÿ</th>
<th>éšæ®µ</th>
<th>ç‹€æ…‹</th>
<th>é©æ‡‰ç—‡</th>
<th>å—è©¦è€…æ•¸</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT00450216</td>
<td>Phase 3</td>
<td>å®Œæˆ</td>
<td>åäºŒæŒ‡è…¸æ½°ç˜(NSAIDç›¸é—œ)</td>
<td>906</td>
</tr>
<tr>
<td>NCT00450658</td>
<td>Phase 3</td>
<td>å®Œæˆ</td>
<td>ä¸Šæ¶ˆåŒ–é“æ½°ç˜</td>
<td>627</td>
</tr>
</tbody>
</table>

<p><strong>è­‰æ“šç­‰ç´šï¼šL2 (æœ‰ Phase 3 è‡¨åºŠè©¦é©—)</strong></p>

<h3>ç›¸é—œæ–‡ç»</h3>

<p>PubMed æœå°‹ç™¼ç¾è±å¯Œçš„æ–‡ç»æ”¯æŒï¼š</p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. duodenal obstruction</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ2 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00450216" target="_blank">NCT00450216</a></td><td>PHASE3</td><td>COMPLETED</td><td>906</td><td>A Randomized, Double-Blind, Phase 3 Study of the Efficacy and Safety of HZT-501 ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00450658" target="_blank">NCT00450658</a></td><td>PHASE3</td><td>COMPLETED</td><td>627</td><td>A Randomized, Double-Blind, Phase 3 Study of the Efficacy and Safety of HZT-501 ...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ3 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/8165479/" target="_blank">8165479</a></td><td>1994</td><td>Article</td><td>Surgical endoscopy</td><td>Giant marginal ulcer.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/9306611/" target="_blank">9306611</a></td><td>1997</td><td>Article</td><td>Surgery today</td><td>Surgical treatment for duodenal involvement in Crohn&#x27;s disea...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2816881/" target="_blank">2816881</a></td><td>1989</td><td>Article</td><td>The American journal</td><td>Failure of single night-time dose of H2-receptor antagonists...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. active peptic ulcer disease</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ19 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/9506245/" target="_blank">9506245</a></td><td>1998</td><td>Article</td><td>Drugs</td><td>Rabeprazole.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2905237/" target="_blank">2905237</a></td><td>1988</td><td>Article</td><td>Drugs</td><td>Prostaglandins, H2-receptor antagonists and peptic ulcer dis...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/3310199/" target="_blank">3310199</a></td><td>1987</td><td>Article</td><td>Scandinavian journal</td><td>Ulcer pain mechanisms. The clinical features of active pepti...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34798155/" target="_blank">34798155</a></td><td>2022</td><td>Article</td><td>International journa</td><td>Famotidine-loaded solid self-nanoemulsifying drug delivery s...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39345794/" target="_blank">39345794</a></td><td>2024</td><td>Article</td><td>Toxicology research</td><td>Diospyros kaki fruit aqueous extract individual/combined wit...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 14 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. peptic ulcer perforation</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ2 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00683111" target="_blank">NCT00683111</a></td><td>PHASE4</td><td>COMPLETED</td><td>500</td><td>Famotidine Compared With Esomeprazole in the Prevention of Ulcer Complications i...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00450658" target="_blank">NCT00450658</a></td><td>PHASE3</td><td>COMPLETED</td><td>627</td><td>A Randomized, Double-Blind, Phase 3 Study of the Efficacy and Safety of HZT-501 ...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ9 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/8165479/" target="_blank">8165479</a></td><td>1994</td><td>Article</td><td>Surgical endoscopy</td><td>Giant marginal ulcer.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/19837071/" target="_blank">19837071</a></td><td>2010</td><td>Article</td><td>Gastroenterology</td><td>Famotidine is inferior to pantoprazole in preventing recurre...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21954519/" target="_blank">21954519</a></td><td>2011</td><td>Article</td><td>Prescrire internatio</td><td>Nonsteroidal anti-inflammatory drugs: add an anti-ulcer drug...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/10379475/" target="_blank">10379475</a></td><td>1999</td><td>Article</td><td>Italian journal of g</td><td>A clinical approach to management of patients with non-stero...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21387691/" target="_blank">21387691</a></td><td>2011</td><td>Article</td><td>Nihon rinsho. Japane</td><td>[Strategy to manage low dose aspirin-induced gastrointestina...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 4 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. gastrojejunal ulcer</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ1 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00557349" target="_blank">NCT00557349</a></td><td>PHASE4</td><td>COMPLETED</td><td>40</td><td>A Randomized, Double-blind Clinical Trial Comparing Zegerid Capsule to Famotidin...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35348552/" target="_blank">35348552</a></td><td>2022</td><td>Article</td><td>The Medical letter o</td><td>Drugs for GERD and peptic ulcer disease.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2028638/" target="_blank">2028638</a></td><td>1991</td><td>Article</td><td>DICP : the annals of</td><td>Famotidine and cardiac arrhythmia.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/8853932/" target="_blank">8853932</a></td><td>1996</td><td>Article</td><td>Clinical pharmacokin</td><td>Pharmacokinetics and pharmacodynamics of famotidine in paedi...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2892567/" target="_blank">2892567</a></td><td>1988</td><td>Article</td><td>British medical jour</td><td>Peptic ulceration.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2875864/" target="_blank">2875864</a></td><td>1986</td><td>Article</td><td>Drugs</td><td>Famotidine. Pharmacodynamic and pharmacokinetic properties a...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. abnormality of glucagon secretion</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.91%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. gastroduodenitis</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.80%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25521726/" target="_blank">25521726</a></td><td>2014</td><td>Article</td><td>Journal of gastroent</td><td>Comparison of teprenone and famotidine against gastroduodena...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/9178671/" target="_blank">9178671</a></td><td>1997</td><td>Article</td><td>Gastroenterology</td><td>Famotidine for healing and maintenance in nonsteroidal anti-...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/7846741/" target="_blank">7846741</a></td><td>1994</td><td>Article</td><td>Therapeutic drug mon</td><td>Pharmacokinetics and pharmacodynamics of famotidine in child...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22066725/" target="_blank">22066725</a></td><td>2012</td><td>Article</td><td>Neurogastroenterolog</td><td>Influence of gastric acid on gastric emptying and gastric di...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/14653238/" target="_blank">14653238</a></td><td>2003</td><td>Article</td><td>Eksperimental&#x27;naia i</td><td>[Laser therapy and famotidine in complex restorative treatme...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. peptic ulcer disease</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.72%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ14 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00683111" target="_blank">NCT00683111</a></td><td>PHASE4</td><td>COMPLETED</td><td>500</td><td>Famotidine Compared With Esomeprazole in the Prevention of Ulcer Complications i...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03667703" target="_blank">NCT03667703</a></td><td>PHASE4</td><td>COMPLETED</td><td>70</td><td>Stress Ulcer Prophylaxis Versus Placebo - a Blinded Randomized Control Trial to ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00839488" target="_blank">NCT00839488</a></td><td>PHASE4</td><td>TERMINATED</td><td>6</td><td>Comparison of Intravenous Pantoprazole and Famotidine for Stress Ulcer Prophylax...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01180179" target="_blank">NCT01180179</a></td><td>PHASE4</td><td>COMPLETED</td><td>228</td><td>Prevention of Recurrent Idiopathic Gastroduodenal Ulcer Bleeding: a Double-blind...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00229424" target="_blank">NCT00229424</a></td><td>PHASE3</td><td>COMPLETED</td><td>325</td><td>Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Cont...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 9 é …è©¦é©—</em></p>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35348552/" target="_blank">35348552</a></td><td>2022</td><td>Article</td><td>The Medical letter o</td><td>Drugs for GERD and peptic ulcer disease.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2573505/" target="_blank">2573505</a></td><td>1989</td><td>Article</td><td>Drugs</td><td>Famotidine. An updated review of its pharmacodynamic and pha...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2875864/" target="_blank">2875864</a></td><td>1986</td><td>Article</td><td>Drugs</td><td>Famotidine. Pharmacodynamic and pharmacokinetic properties a...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2905237/" target="_blank">2905237</a></td><td>1988</td><td>Article</td><td>Drugs</td><td>Prostaglandins, H2-receptor antagonists and peptic ulcer dis...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34798155/" target="_blank">34798155</a></td><td>2022</td><td>Article</td><td>International journa</td><td>Famotidine-loaded solid self-nanoemulsifying drug delivery s...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. multiple endocrine neoplasia</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.69%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ3 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05417594" target="_blank">NCT05417594</a></td><td>PHASE1, PHASE2</td><td>RECRUITING</td><td>695</td><td>A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tole...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01248962" target="_blank">NCT01248962</a></td><td>PHASE2</td><td>COMPLETED</td><td>146</td><td>Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00451880" target="_blank">NCT00451880</a></td><td>PHASE1</td><td>COMPLETED</td><td>180</td><td>A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL281 Admi...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ1 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2874977/" target="_blank">2874977</a></td><td>1986</td><td>Article</td><td>Drugs</td><td>Current management of Zollinger-Ellison syndrome.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. acne (disease)</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.55%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

Famotidine åœ¨å°ç£æœ‰å¤šç¨®åŠ‘å‹å’Œå“ç‰Œä¸Šå¸‚ï¼š

| è¨±å¯è­‰å­—è™Ÿ | ä¸­æ–‡å“å | åŠ‘å‹ | è¨±å¯è­‰æŒæœ‰è€… | ç‹€æ…‹ |
|-----------|---------|------|-------------|------|
| è¡›ç½²è—¥è£½å­—ç¬¬037684è™Ÿ | è«¾å¾—èˆ’èƒƒç¦æ²»æ½°è†œè¡£éŒ 40æ¯«å…‹ | è†œè¡£éŒ  | ç´„å…‹è£½è—¥è‚¡ä»½æœ‰é™å…¬å¸ | æœ‰æ•ˆ |
| è¡›ç½²è—¥è£½å­—ç¬¬034815è™Ÿ | èƒƒåº·èˆ’è†œè¡£éŒ 20æ¯«å…‹ | è†œè¡£éŒ  | æ°¸ä¿¡è—¥å“å·¥æ¥­è‚¡ä»½æœ‰é™å…¬å¸ | æœ‰æ•ˆ |
| è¡›ç½²è—¥è£½å­—ç¬¬036152è™Ÿ | æ³•ç‘ªä¹³é “è† å›Š20æ¯«å…‹ | è† å›Š | ä¸­åœ‹åŒ–å­¸è£½è—¥è‚¡ä»½æœ‰é™å…¬å¸ | æœ‰æ•ˆ |

**åŠ‘å‹å¤šæ¨£**ï¼šéŒ åŠ‘ã€è† å›Šã€æ³¨å°„åŠ‘ã€å£æº¶éŒ ç­‰

## å®‰å…¨æ€§è€ƒé‡

### å·²çŸ¥é¢¨éšª
- **æ•´é«”å®‰å…¨æ€§è‰¯å¥½**ï¼šH2 æ‹®æŠ—åŠ‘æ˜¯æœ€å®‰å…¨çš„æŠ‘é…¸è—¥ç‰©ä¹‹ä¸€
- **é ­ç—›**ï¼šæœ€å¸¸è¦‹çš„å‰¯ä½œç”¨(ç´„ 4%)
- **è…¸èƒƒä¸é©**ï¼šä¾¿ç§˜ã€è…¹ç€‰
- **è¡€æ¶²å­¸ç•°å¸¸**ï¼šç½•è¦‹çš„è¡€å°æ¿æ¸›å°‘ç—‡

### è—¥ç‰©äº¤äº’ä½œç”¨
æ ¹æ“š DDInter è³‡æ–™åº«ï¼š

| äº¤äº’ä½œç”¨è—¥ç‰© | åš´é‡åº¦ | èªªæ˜ |
|-------------|--------|------|
| Ketoconazole | Moderate | æ¸›å°‘ ketoconazole å¸æ”¶ |
| Atazanavir | Major | æ¸›å°‘ atazanavir å¸æ”¶ï¼Œé¿å…ä½µç”¨ |
| Delavirdine | Major | æ¸›å°‘ delavirdine å¸æ”¶ |
| Dasatinib | Moderate | å¯èƒ½æ¸›å°‘å¸æ”¶ |

### ç‰¹æ®Šæ—ç¾¤
- **å­•å©¦**ï¼šB ç´šï¼Œç›¸å°å®‰å…¨
- **å“ºä¹³**ï¼šåˆ†æ³Œè‡³ä¹³æ±ï¼Œå»ºè­°è¬¹æ…ä½¿ç”¨
- **è…åŠŸèƒ½ä¸å…¨**ï¼šCrCl < 50 mL/min éœ€æ¸›é‡
- **è€å¹´äºº**ï¼šä¸€èˆ¬ç„¡éœ€èª¿æ•´åŠ‘é‡

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

**å’–å•¡å› ï¼ˆå’–å•¡ã€èŒ¶ã€å¯æ¨‚ï¼‰** ğŸŸ¢ Minor
- å½±éŸ¿ï¼šH2 é˜»æ–·åŠ‘å¯èƒ½å¢åŠ å’–å•¡å› å¸æ”¶
- å»ºè­°ï¼šç„¡éœ€ç‰¹åˆ¥é™åˆ¶


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**è…è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- å¯èƒ½éœ€è¦èª¿æ•´åŠ‘é‡ã€‚é¢¨éšªåŒ…æ‹¬ï¼šç™²ç™‡ç™¼ä½œã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**Peptic Ulcer Hemorrhage** ğŸŸ¢ Minor
- ä¸æ‡‰ä½¿ç”¨æœ¬è—¥ç‰©ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

### æ•´é«”è©•ä¼°
æ­¤é æ¸¬**å·²æœ‰å……åˆ†è‡¨åºŠè­‰æ“šæ”¯æŒ**ï¼ŒåŸå› å¦‚ä¸‹ï¼š
1. é æ¸¬é©æ‡‰ç—‡èˆ‡åŸæ ¸å‡†é©æ‡‰ç—‡é«˜åº¦é‡ç–Š
2. æœ‰å¤šå€‹ RCT å’Œç³»çµ±æ€§å›é¡§æ”¯æŒ
3. è—¥ç†æ©Ÿè½‰æ˜ç¢º
4. é•·æœŸå®‰å…¨æ€§è³‡æ–™å®Œæ•´

### å»ºè­°è¡Œå‹•
- [x] é€™äº›é©æ‡‰ç—‡åœ¨è‡¨åºŠå¯¦å‹™ä¸­å·²è¢«å»£æ³›ä½¿ç”¨
- [ ] å¯è€ƒæ…®å‘ TFDA ç”³è«‹é©æ‡‰ç—‡æ“´å±•ï¼ˆå¦‚æ˜ç¢ºçš„ã€ŒåäºŒæŒ‡è…¸èƒƒé€†æµã€é©æ‡‰ç—‡ï¼‰
- [ ] æŒçºŒç›£æ¸¬é•·æœŸä½¿ç”¨çš„å®‰å…¨æ€§

### è‡¨åºŠå»ºè­°
Famotidine å¯å®‰å…¨ç”¨æ–¼ï¼š
- è¼•è‡³ä¸­åº¦æ¶ˆåŒ–æ€§æ½°ç˜
- NSAID ç›¸é—œæ½°ç˜çš„é é˜²
- èƒƒé£Ÿé“é€†æµç–¾ç—…
- æ‡‰æ¿€æ€§æ½°ç˜é é˜²

å°æ–¼è¼ƒåš´é‡çš„ç—…ä¾‹ï¼Œå¯è€ƒæ…®ä½¿ç”¨ PPI é¡è—¥ç‰©ã€‚

### é¢¨éšªç­‰ç´š
**ä½é¢¨éšª** - å¯åœ¨é©ç•¶é©æ‡‰ç—‡ä¸‹å®‰å…¨ä½¿ç”¨

---

*å ±å‘Šç”Ÿæˆæ—¥æœŸï¼š2026-02-11*
*è³‡æ–™ä¾†æºï¼šTxGNN é æ¸¬ã€ClinicalTrials.govã€PubMedã€TFDA*

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Urea]({{ "/drugs/urea/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Alprostadil]({{ "/drugs/alprostadil/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Threonine]({{ "/drugs/threonine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Levamisole]({{ "/drugs/levamisole/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Tioconazole]({{ "/drugs/tioconazole/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Famotidineè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/famotidine/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_famotidine,
  title = {Famotidineè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/famotidine/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
